Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

EXACT Therapeutics

Less than 1K followers

EXTX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

EXACT Therapeutics operates in the medical technology sector. The company specializes in the development of medical devices. The product portfolio is broad and includes, for example, technical platforms for drug testing. In addition to the main business, related ancillary services and value-added products are also offered. The business is operated globally with the largest presence in the Nordic market. The company was previously known as Phoenix Solutions and is headquartered in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
13.3.
2026

Extraordinary general meeting '26

8.4.
2026

Annual report '25

12.6.
2026

General meeting '26

All
Press releases
ShowingAll content types
Regulatory press release3/3/2026, 1:15 PM

EXACT Therapeutics - First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer

EXACT Therapeutics
Regulatory press release2/27/2026, 12:16 PM

EXACT Therapeutics AS: Notice of extraordinary general meeting

EXACT Therapeutics
Regulatory press release2/27/2026, 7:54 AM

EXACT Therapeutics AS: Warrants exercise

EXACT Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release2/12/2026, 9:48 AM

EXTX: Financial calendar

EXACT Therapeutics
Regulatory press release2/11/2026, 7:00 AM

EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program

EXACT Therapeutics
Regulatory press release2/6/2026, 7:30 AM

EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program

EXACT Therapeutics
Regulatory press release2/5/2026, 12:19 PM

EXACT Therapeutics: Correction of final warrants exercise date

EXACT Therapeutics
Regulatory press release2/5/2026, 8:17 AM

EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders

EXACT Therapeutics
Regulatory press release2/5/2026, 7:30 AM

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

EXACT Therapeutics
Regulatory press release1/27/2026, 7:00 AM

EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants

EXACT Therapeutics
Regulatory press release1/8/2026, 7:30 AM

EXTX: EXACT Therapeutics' Phase 2 trial in pancreatic cancer patients to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium

EXACT Therapeutics
Regulatory press release11/25/2025, 11:57 AM

EXTX: EXACT Therapeutics to present company update

EXACT Therapeutics
Regulatory press release11/24/2025, 7:25 AM

EXACT Therapeutics AS: New option program and receipt of share options by primary insiders

EXACT Therapeutics
Regulatory press release9/25/2025, 6:00 AM

EXTX: EXACT Therapeutics first half 2025 interim results

EXACT Therapeutics
Regulatory press release9/18/2025, 6:00 AM

EXTX: EXACT Therapeutics' Phase 2 trial to be presented at the 2025 AACR Special Conference

EXACT Therapeutics
Regulatory press release9/9/2025, 6:00 AM

EXTX: EXACT Therapeutic's Acoustic Cluster Therapy to be presented at the Ninth International Cancer lmmunotherapy Conference

EXACT Therapeutics
Regulatory press release8/12/2025, 6:30 AM

EXTX: EXACT Therapeutics to Present at the European Society for Medical Oncology (ESMO) Congress 2025

EXACT Therapeutics
Regulatory press release8/11/2025, 9:08 AM

EXTX: Financial calendar

EXACT Therapeutics
Regulatory press release7/8/2025, 6:30 AM

EXTX: EXACT Therapeutics announces grant of core patent in the U.S.

EXACT Therapeutics
Regulatory press release6/24/2025, 6:00 AM

EXTX: EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

EXACT Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.